Lördag 21 December | 13:46:27 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-11-12 07:00 Kvartalsrapport 2025-Q3
2025-08-21 07:00 Kvartalsrapport 2025-Q2
2025-05-15 07:00 Kvartalsrapport 2025-Q1
2025-02-20 08:00 Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-01 - Split LIFE 13:1
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - Extra Bolagsstämma 2024
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-05-08 - X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 - Årsstämma
2022-04-21 - Bokslutskommuniké 2021
2021-09-30 - Extra Bolagsstämma 2021
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 - Årsstämma
2021-04-20 - Bokslutskommuniké 2020
2020-06-26 - Årsstämma
2020-06-01 - Bokslutskommuniké 2019
2019-02-07 - Split LIFE 4:1
2018-12-11 - Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2023-11-20 08:00:00

Bergen, Norway, November 20th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare Laboratory (Mainz, Germany) has been successfully audited as part of the upcoming ISO 13485 certification.

Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of August 20th, 2023, and later investor communication. The launch of an automated production line at Lifecare Laboratory by end of Q2 2024 is set as a major milestone, and on this basis the company aim to launch the first product in the veterinary market mid 2024.

Last week, the ISO 13495 audit was conducted, and finalized, at Lifecare Laboratory. The purpose of the audit was to review Lifecare’s Quality Management System in context of ISO 13485. The audit was concluded without any major findings, and consequently Lifecare Laboratory will be recommended for ISO 13485 certification.

Lifecare expect the ISO 13485 certificate will be issued early in 2024. This progress is in accordance with the current list of communicated trigger events. - Passing this milestone is a very important achievement for Lifecare, The Lifecare QMS-team in Bergen and Mainz has worked dedicatedly and systematically towards this goal and has proven their high standards, dedication and progress when it comes to quality management. This is confirming a solid fundament for our continued work on regulatory processes, says CEO Joacim Holter at Lifecare.

ISO 13485 is a Quality Management System specific to medical devices and covers the entire life cycle of a device, from design and development to production, installation, and servicing. - Safety and quality are non-negotiable in the medical devices industry, that’s why we decided to certify for the ISO 13485, says Senior QMS Manager Barbora Tencer.

According to the International Organization for Standardization (ISO) regulatory requirements are increasingly stringent throughout every step of a product’s life cycle, including service and delivery. Increasingly, organizations in the industry are xpected to demonstrate their quality management processes and ensure best practice in everything they do. This internationally agreed standard sets out the requirements for a quality management system specific to the medical devices industry.

Lifecare Laboratory was ISO 9001 certified in April 2023. To be also be compliant with ISO 13485 is an important step on the route towards Lifecare’s ultimate goal; product CE mark necessary to enter the market with a medical device for humans.

- It is vital for the integrity of the production of Sencell Continuous Glucose Monitor, and later commercialization of the product, that our Quality Management System are certified. We depend on the trust from the market and patient groups, that our processes meet international quality standards. It is therefore very motivating to successfully complete the ISO 13485 audit in accordance with the planned and communicated timeline. This is solid confirmation that Lifecares operations are compliant with the standards necessary to develop and produce medical devices. Lifecare will continue to improve our standards and quality systems to ensure regulatory compliance in our upcoming operations, says CEO Joacim Holter.